Furthermore, a therapeutic NPC vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost the immunity targeting EBV EBNA1, LMP2 by two cooperating groups from Hong Kong and the United Kingdom [105,106]. This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.